Maxim Group Downgrades Reviva Pharmaceuticals to Hold
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Jason McCarthy has downgraded Reviva Pharmaceuticals (NASDAQ:RVPH) from Buy to Hold.
August 16, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Maxim Group analyst Jason McCarthy has downgraded Reviva Pharmaceuticals from Buy to Hold, indicating a less optimistic outlook on the stock.
The downgrade from Buy to Hold by a reputable analyst suggests a less favorable view on the stock's short-term performance, likely leading to a negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100